Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review
Authors:
- 15 March 2018
- journal article
- review article
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 33 (3) , 969-976
Abstract
The aim of this study is to compare the efficacy of bromocriptine (BRC) versus cabergoline (CAB) in patients with giant prolactinomas. We searched MEDLINE, EMBASE, CENTRAL and Clinical Trials.gov for studies dated before March 1st, 2016, that used BRC or CAB for the treatment of patients with giant prolactinomas. Specific eligibility criteria were set to identify articles and cases. The selected articles were reviewed, and the data were extracted for analysis. The compared outcomes included tumor shrinkage, tumor response, normalization of prolactin (PRL) level, and visual field defect (VFD) improvement. Gender differences were also considered. Differences between the groups were assessed using Student’s t test and the chi-square test. Two hundred and forty-five records were identified, and 10 articles and 104 cases met the inclusion criteria. Based on our analysis, CAB is significantly better than BRC in normalizing PRL levels in patients, especially males, with giant prolactinomas (69.4% versus 31.7%, p = 0.01). However, there was no significant difference between the two drugs in terms of tumor shrinkage, tumor response and VFD improvement (p > 0.05) in male or female patients. CAB exhibits significantly better efficacy than BRC in the normalization of PRL levels in male patients with giant prolactinomas. Regarding tumor reduction and VFD improvement, both drugs are comparably effective for patients of both genders. This quantitative and systematic review provides preliminary evidence in favor of CAB as a medical therapy for treating giant prolactinomas in male patients, especially those with extremely high PRL levels.Keywords
Funding Information
- National Natural Science Foundation of China (81471392, 81671371)
- Shanghai Municipal Education Commission (20161407)
This publication has 44 references indexed in Scilit:
- Giant prolactinomas: the therapeutic approachClinical Endocrinology, 2013
- Medical treatment of prolactinomasNature Reviews Endocrinology, 2011
- Comparison of cabergoline and bromocriptine in patients with asymptomatic incidental hyperprolactinemia undergoing ICSI-ETGynecological Endocrinology, 2010
- Efficacy and Safety of Cabergoline as First Line Treatment for Invasive Giant ProlactinomaJournal of Korean Medical Science, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Drug Insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and womenNature Clinical Practice Endocrinology & Metabolism, 2006
- Dopamine receptor agonists for treating prolactinomasExpert Opinion on Investigational Drugs, 2002
- Comparison of the Effects of Cabergoline and Bromocriptine on Prolactin Levels in Hyperprolactinemic Patients.Internal Medicine, 2001
- Volume of Pituitary MacroadenomasJournal of Computer Assisted Tomography, 1992
- THE EFFECTS OF BROMOCRIPTINE ON THE SEXUAL BEHAVIOUR OF HYPERPROLACTINAEMIC MAN: A CONTROLLED CASE STUDYClinical Endocrinology, 1984